CGP 23996

nonreducible analog of somatostatin; used to test binding sites for somatostatin

Also Known As:

1-des-Ala-2-desamino-Gly-3-Cys-11-Tyr-3,14-dicarbasomatostatin; CGP-23996; somatostatin, des-Ala(1)-desamino-Gly(2)-Cys(3)-Tyr(11)-dicarba(3,14)-; somatostatin, desalanyl(1)-desaminoglycyl(2)-cysteinyl(3)-tyrosyl(11)-dicarba(3,14)-; 3,14-Dicarbasomatostatin, 1-de-L-alanine-2-deglycine-3-butanoic acid-11-L-tyrosine-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

Seizures (Absence Seizure)

12/01/1996 - "A significant decrease (about 40%) of somatostatin receptor binding sites was observed in the molecular layer of the dentate gyrus with all radioligands (except [125I]CGP 23996 in Na+ buffer, which did not label this area) at stage 2 (pre-convulsive stage) and one week, but not one month, after stage 5 (generalized motor seizures). "
04/01/1995 - "In situ hybridization histochemistry for somatostatin receptors-1, -2, -3 and -4 section and receptor autoradiography using [125I]CGP 23996, [125I]somatostatin-28, [125I]seglitide and [125I]Tyr3 octreotide were carried out to determine the expression of somatostatin receptor messenger RNAs and binding sites in the hippocampus and cerebral cortex of rats 21 days following generalized limbic seizures induced by subcutaneous injection of 12mg/kg kainic acid. "

Related Drugs and Biologics

1.	Somatostatin Receptors (Somatostatin Receptor)
2.	Somatostatin-28
3.	Octreotide (Sandostatin)
4.	Somatostatin (Somatotropin Release-Inhibiting Factor)
5.	Kainic Acid (Kainate)
6.	Buffers
7.	seglitide

Related Therapies and Procedures

1.	Subcutaneous Injections